Fierce's J.P. Morgan 2012 executive chats, recapped

We had a great time in San Francisco this week huddling around the Westin St. Francis for J.P. Morgan's 30th Healthcare Conference. Mark Hollmer gave us a fly-on-the-wall take on the mood Wednesday. John Carroll and Ryan McBride joined Mark recapping "mixed feelings" biotechnology executives are starting the year with. 

We also set a mission to meet with the newsmakers driving drug and device development. Here's a quick run-down of some of the players our editorial team spoke with, complete with links to their J. P. Morgan slide show page.

Richard Pops
Chairman and CEO
Alkermes EDT acquisition, Risperdal, Bydureon, CNS pipeline
Olav Hellebø
CEO
Clavis Pharma CP-4126, pancreatic cancer, gemcitabine
Chuck Bramlage
CEO
Pearl Therapeutics COPD, midstage PT003 studies, partnerships
Charles Carignan
President and CEO
NinePoint Medical Nvision VLE 510(k) clearance, high-resolution imaging, startups
Jim Mullen
CEO
Patheon Manufacturing fundamentals, Phase I molecules, consolidation
Francois Nader
President and CEO
NPS Pharmaceuticals Injectable orphan drugs, commercialization shift
Noubar Afeyan
CEO
Flagship Ventures Exclusive: $270m fund | New generation of drug discovery
Dave Rosa
CEO
Sunshine Heart Implantable balloon counter-pulsation device, pivotal trial launch
Andreas Sundquist 
Co-founder and CEO
DNAnexus Google Ventures, genomic data platformization
Steven Tregay
CEO
Forma Therapeutics Big pharma collaborations, small-molecule attacks on tumors
Tuan Ha-Ngoc
President and CEO
Aveo Pharmaceuticals Positive tivozanib data, renal cell carcinoma
Roger Tung
President and CEO
Concert Pharmaceuticals Deuterium drug platform, CTP-499, diabetic nephropathy
James E. Brown
CEO
Durect Phase III Posidur abdominal data

Editor's Note: FierceBiotech won't be published Monday, Jan. 16, in honor of Martin Luther King Jr. Day. We will return to our regular schedule Tuesday, Jan. 17.

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.